NCT03171064View on ClinicalTrials.gov

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

July 30, 2022

Study Completion Date

December 1, 2022

Conditions
PD-1 AntibodiesExerciseMelanoma
Interventions
BEHAVIORAL

Resistance and Endurance Exercise

Machine-based, 2x/week endurance and resistance training for 12 weeks

Trial Locations (1)

69120

Heidelberg University Clinic, Heidelberg

All Listed Sponsors
collaborator

Department of Dermatology, Heidelberg University Hospital

UNKNOWN

lead

University Hospital Heidelberg

OTHER

NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment | Biotech Hunter | Biotech Hunter